Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew R Smith

Showing results (241-250 of 319) with videos related to

Pageof 32
Sort By:
Clinical Genitourinary Cancer|May 9, 2014
Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancerGuru Sonpavde, Gregory R Pond, Andrew J Armstrong, et al.
European Urology|September 24, 2024
Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE TrialDana E Rathkopf, Guilhem Roubaud, Kim N Chi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2014
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)Matthew R Smith, Susan Halabi, Charles J Ryan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2017
Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical TrialsGlenn Heller, Robert McCormack, Thian Kheoh, et al.
Nature|December 22, 2007
Isolation of rare circulating tumour cells in cancer patients by microchip technologySunitha Nagrath, Lecia V Sequist, Shyamala Maheswaran, et al.
BJU International|December 5, 2013
Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancerGuru Sonpavde, Gregory R Pond, Andrew J Armstrong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2018
Reply to C. Ren et alGlenn Heller, Robert McCormack, Thian Kheoh, et al.
Eclinicalmedicine|May 30, 2023
Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancerCelestia S Higano, Daniel J George, Neal D Shore, et al.
The Lancet. Oncology|September 15, 2018
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trialFred Saad, David Cella, Ethan Basch, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids|May 24, 2024
Linoleic acid blunts early osteoblast differentiation and impairs oxidative phosphorylation in vitroPaula-Dene C Nesbeth, Thomas R Ziegler, Ashish Kumar Tripathi, et al.
Pageof 32

Showing results (241-250 of 319) with videos related to

Sort By:
Pageof 32
Clinical Genitourinary Cancer|May 9, 2014
Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancerGuru Sonpavde, Gregory R Pond, Andrew J Armstrong, et al.
European Urology|September 24, 2024
Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE TrialDana E Rathkopf, Guilhem Roubaud, Kim N Chi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2014
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)Matthew R Smith, Susan Halabi, Charles J Ryan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2017
Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical TrialsGlenn Heller, Robert McCormack, Thian Kheoh, et al.
Nature|December 22, 2007
Isolation of rare circulating tumour cells in cancer patients by microchip technologySunitha Nagrath, Lecia V Sequist, Shyamala Maheswaran, et al.
BJU International|December 5, 2013
Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancerGuru Sonpavde, Gregory R Pond, Andrew J Armstrong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2018
Reply to C. Ren et alGlenn Heller, Robert McCormack, Thian Kheoh, et al.
Eclinicalmedicine|May 30, 2023
Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancerCelestia S Higano, Daniel J George, Neal D Shore, et al.
The Lancet. Oncology|September 15, 2018
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trialFred Saad, David Cella, Ethan Basch, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids|May 24, 2024
Linoleic acid blunts early osteoblast differentiation and impairs oxidative phosphorylation in vitroPaula-Dene C Nesbeth, Thomas R Ziegler, Ashish Kumar Tripathi, et al.
Pageof 32